Literature DB >> 23619892

Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging.

Ruth Cohen1, Danielle J Vugts, Marijke Stigter-van Walsum, Gerard W M Visser, Guus A M S van Dongen.   

Abstract

IRDye800CW and zirconium-89 ((89)Zr) have very attractive properties for optical imaging and positron emission tomography (PET) imaging, respectively. Here we describe a procedure for dual labeling of mAbs with IRDye800CW and (89)Zr in a current good manufacturing practice (cGMP)-compliant way. IRDye800CW and (89)Zr are coupled inertly, without impairment of immunoreactivity and pharmacokinetics of the mAb. Organ and whole-body distribution of the final product can be assessed by optical and PET imaging, respectively. For this purpose, a minimal amount of the chelate N-succinyldesferrioxamine (N-sucDf) is first conjugated to the mAb. Next, N-sucDf-mAb is conjugated with IRDye800CW, after which the N-sucDf-mAb-IRDye800CW is labeled with (89)Zr. After each of these three steps, the product is purified by gel filtration. The sequence of this process avoids unnecessary radiation exposure to personnel and takes about 5 h. The process can be scaled up by the production of large batches of premodified mAbs that can be dispensed and stored until they are labeled with (89)Zr.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23619892     DOI: 10.1038/nprot.2013.054

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  24 in total

1.  Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.

Authors:  F B van Gog; G W Visser; R Klok; R van der Schors; G B Snow; G A van Dongen
Journal:  J Nucl Med       Date:  1996-02       Impact factor: 10.057

Review 2.  89Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals.

Authors:  Danielle J Vugts; Gerard W M Visser; Guus A M S van Dongen
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

3.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.

Authors:  Maria J W D Vosjan; Lars R Perk; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
Journal:  Nat Protoc       Date:  2010-03-25       Impact factor: 13.491

4.  Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice.

Authors:  Fang Wu; Mitalee Tamhane; Marilyn E Morris
Journal:  AAPS J       Date:  2012-03-06       Impact factor: 4.009

5.  Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice.

Authors:  A Pèlegrin; S Folli; F Buchegger; J P Mach; G Wagnières; H van den Bergh
Journal:  Cancer       Date:  1991-05-15       Impact factor: 6.860

Review 6.  Tissue distribution studies of protein therapeutics using molecular probes: molecular imaging.

Authors:  Simon-Peter Williams
Journal:  AAPS J       Date:  2012-03-31       Impact factor: 4.009

7.  Development of agents for reinforcement of fluorescence on near-infrared ray excitation for immunohistological staining.

Authors:  S Ito; N Muguruma; S Hayashi; S Taoka; T Bando; K Inayama; M Sogabe; T Okahisa; S Okamura; H Shibata; T Irimura; K Takesako; S Shibamura
Journal:  Bioorg Med Chem       Date:  1998-05       Impact factor: 3.641

8.  Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.

Authors:  Lakshmi Sampath; Sunkuk Kwon; Shi Ke; Wei Wang; Rachel Schiff; Michel E Mawad; Eva M Sevick-Muraca
Journal:  J Nucl Med       Date:  2007-09       Impact factor: 10.057

9.  89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.

Authors:  Iris Verel; Gerard W M Visser; Ronald Boellaard; Marijke Stigter-van Walsum; Gordon B Snow; Guus A M S van Dongen
Journal:  J Nucl Med       Date:  2003-08       Impact factor: 10.057

10.  Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats.

Authors:  Milton V Marshall; Daniel Draney; Eva M Sevick-Muraca; D Michael Olive
Journal:  Mol Imaging Biol       Date:  2010-12       Impact factor: 3.488

View more
  25 in total

1.  A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting.

Authors:  Carlos Pérez-Medina; Dalya Abdel-Atti; Yachao Zhang; Valerie A Longo; Chrisopher P Irwin; Tina Binderup; Jesús Ruiz-Cabello; Zahi A Fayad; Jason S Lewis; Willem J M Mulder; Thomas Reiner
Journal:  J Nucl Med       Date:  2014-07-24       Impact factor: 10.057

2.  Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle.

Authors:  Daniel L J Thorek; David Ulmert; Ndeye-Fatou M Diop; Mihaela E Lupu; Michael G Doran; Ruimin Huang; Diane S Abou; Steven M Larson; Jan Grimm
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

3.  Fluorescence Lifetime-Based Tumor Contrast Enhancement Using an EGFR Antibody-Labeled Near-Infrared Fluorophore.

Authors:  Rahul Pal; Homan Kang; Hak Soo Choi; Anand T N Kumar
Journal:  Clin Cancer Res       Date:  2019-09-03       Impact factor: 12.531

4.  Development and characterization of CD54-targeted immunoPET imaging in solid tumors.

Authors:  Weijun Wei; Dawei Jiang; Hye Jin Lee; Miao Li; Christopher J Kutyreff; Jonathan W Engle; Jianjun Liu; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-11       Impact factor: 9.236

5.  89Zr-Chloride Can Be Used for Immuno-PET Radiochemistry Without Loss of Antigen Reactivity In Vivo.

Authors:  Darpan N Pandya; Nikunj B Bhatt; Frankis Almaguel; Stephanie Rideout-Danner; Howard D Gage; Kiran Kumar Solingapuram Sai; Thaddeus J Wadas
Journal:  J Nucl Med       Date:  2018-11-15       Impact factor: 10.057

6.  A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents.

Authors:  Nikunj B Bhatt; Darpan N Pandya; Stephanie Rideout-Danner; Howard D Gage; Frank C Marini; Thaddeus J Wadas
Journal:  Dalton Trans       Date:  2018-09-04       Impact factor: 4.390

7.  Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.

Authors:  Cornelius Cilliers; Bruna Menezes; Ian Nessler; Jennifer Linderman; Greg M Thurber
Journal:  Cancer Res       Date:  2017-12-07       Impact factor: 12.701

8.  Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.

Authors:  Kirstin A Zettlitz; Wen-Ting K Tsai; Scott M Knowles; Naoko Kobayashi; Timothy R Donahue; Robert E Reiter; Anna M Wu
Journal:  J Nucl Med       Date:  2018-03-30       Impact factor: 10.057

9.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

Review 10.  Dual PET and Near-Infrared Fluorescence Imaging Probes as Tools for Imaging in Oncology.

Authors:  Fei-Fei An; Mark Chan; Harikrishna Kommidi; Richard Ting
Journal:  AJR Am J Roentgenol       Date:  2016-05-25       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.